# US 2012/0252852 A1 · Otamixaban formulations with improved stability

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252852 A1
- Document ID: US20120252852A1
- Status: Published application
- Kind: A1
- Application number: 13/431,571
- Filed: 2012-03-27
- Published: 2012-10-04
- Earliest claimed: 2011-03-29
- Assignees: Sanofi
- Inventors: Walter KAMM; Till Bussemer; Doris Andert; Bernd Kühn; Ernst-Josef Todt
- Web page: https://patentgrep.com/patent/US20120252852A1

## CPC

- A61K 31/4425: Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/10: for osteoporosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a pharmaceutical composition comprising methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

## Claims

### Claim 1

An aqueous pharmaceutical composition for injection comprising
a) from 0.1 mg/mL to 60 mg/mL methyl (2R,3R)-2-{3-[amino(imino) methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate and
b) from 1 mMol/L to 1000 mMol/L acidic reacting compound or its salt or a mixture thereof, said composition having
a pH from about pH 3 to about pH 5.0.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1 wherein said acidic reacting compound is selected from the group consisting of citric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid, ascorbic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicyclic acid, 2-phenoxybenzoic acid, p-toluenesulfonic acid, methanesulfonic acid, 2-hydroxyethanesulfonic acid, hyaluronic acid, acetyl salicylic acid or amino acids or mineral acids selected from the group consisting of hydrochloride acid or phosphoric acid or salts of said organic acids, amino acids and mineral acids or a mixture of one or more of said acidic reacting compounds.

### Claim 3 (depends on 2)

The pharmaceutical composition according to claim 2 wherein said acidic reacting compound is selected from citric acid and sodium citrate or a mixture thereof.

### Claim 4 (depends on 1)

The aqueous pharmaceutical composition according to claim 1 comprising from 1.0 mg/mL to 50 mg/mL methyl (2R,3R)-2-{3-[amino(imino) methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate and from 20 mMol to 25 mMol acidic reacting compound or its salt or a mixture thereof.

### Claim 5 (depends on 4)

An aqueous pharmaceutical composition according to claim 4 comprising from 1.0 mg/mL to 5 mg/mL methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate and
from 20 mMol to 25 mMol acidic reacting compound or its salt or a mixture thereof.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1 wherein the aqueous pharmaceutical composition posses a pH from about pH 3 to about pH 4.7 to an aqueous solution or dispersion of the pharmaceutical composition.

### Claim 7 (depends on 6)

The pharmaceutical composition according to claim 6 wherein said acidic reacting compound creates a pH from about pH 3.7 to about pH 4.3.

### Claim 8 (depends on 6)

The pharmaceutical composition according to claim 6 wherein said acidic reacting compound creates a pH from about pH 4.0 to about pH 4.2.

### Claim 9 (depends on 1)

The pharmaceutical composition according to claim 1 containing a maximum impurity level of (2R,3R)-2-(3-Carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl)benzoylamino]-butyric acid that does not exceed about 8.0% after long term storage.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9 wherein said maximum impurity level is from 0.3% to 4.0%.

### Claim 11 (depends on 1)

The pharmaceutical composition according to claim 1 containing a maximum impurity level of (2R,3R)-2-(3-Carbamoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl)benzoylamino]-butyric acid methyl ester that does not exceed about 5.0% after long term storage.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11 wherein said maximum impurity level is from 0.7% to 4.5%.

### Claim 13 (depends on 1)

The pharmaceutical composition according to claim 1 wherein said pharmaceutical composition is sterile.

### Claim 14 (depends on 1)

A method of treating acute myocardial infarction, non-ST elevation myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy, percutaneous transluminal coronary angioplasty, transient ischemic attacks, stroke, intermittent claudication and restenosis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition according to claim 1.

### Claim 15 (depends on 9)

The pharmaceutical composition according to claim 9 wherein said maximum impurity level is from 0.4% to 1.8%.

### Claim 16 (depends on 11)

The pharmaceutical composition according to claim 11 wherein said maximum impurity level is from 0.9% to 3.5%.
